Navigation Links
CEL-SCI Receives Payment From Marketing Partner
Date:3/10/2010

CEL-SCI will be responsible for manufacturing the product, while Byron will be responsible for sales in the Territory. Revenues will be split 50/50 between CEL-SCI and Byron.

"We are pleased that Byron has elected to make this payment to maintain its rights in the Territory," said Geert Kersten, Chief Executive Officer of CEL-SCI. "We are continuing to seek marketing and development partners in other emerging markets, while maintaining rights to key markets, even as we prepare to commence a pivotal Phase III study for Multikine in head and neck cancer.  Fortunately we are in a financially strong position allowing us to proceed in this manner."  Head and neck cancer is one of the world's biggest cancers affecting about 650,000 people per annum worldwide.

CEL-SCI is developing Multikine for approval as a first-line indication in newly diagnosed head and neck cancer. To that end, the Company's planned Phase III clinical trial is an 800 patient randomized, controlled clinical study designed to demonstrate that administration of its cancer drug Multikine to head and neck cancer patients before they receive any other conventional cancer treatment will increase their overall survival.  In Phase II clinical trials Multikine was shown to be safe and well-tolerated, and to improve the patients' overall survival by 33% at a median of three and a half years following surgery.


'/>"/>
SOURCE CEL-SCI Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
2. CEL-SCI Corporation Releases Letter to Shareholders
3. CEL-SCI Corporation Reports First Quarter 2010 Financial Results
4. CEL-SCI to Present at 12th Annual BIO CEO & Investor Conference
5. CEL-SCI Hires Vice President of Manufacturing/Facilities and Commercial Operations
6. CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine
7. CEL-SCI Retains Global Contract Research Organization to Manage Upcoming Phase III Clinical Trial for Its Cancer Drug Multikine
8. CEL-SCI Corporation Releases Letter to Shareholders
9. CEL-SCI Hires Clinical Research Organization for Clinical Study With Hospitalized H1N1-Infected Patients
10. CEL-SCI Expands H1N1 Flu Virus Work
11. CEL-SCI to Present Data from Multikine Clinical Trials at National Institutes of Health (NIH), National Cancer Institute (NCI) Seminar Series
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Md. , May 22, 2015  RegeneRx ... today announced a peer-reviewed publication of the results ... evaluating RGN-259 (RegeneRx,s preservative-free eye drops) for the ... controlled adverse environment (CAE ® ) model.  The ... the results, which were previously disseminated by the ...
(Date:5/22/2015)... 2015 According to a new ... (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive ... by End Users - Global Forecast to 2020", published ... to reach $736.85 Million by 2020 from $452.36 Million ... Browse 71 market data Tables and 90 ...
(Date:5/22/2015)... May 22, 2015   InspireMD, Inc. (NYSE MKT: ... protection systems ("EPS"), today announced that its CGuard TM ... principle investigator Prof. Piotr Musialek , at the ... Paris, France . PARADIGM, an investigator-initiated ... c A roti D revascularization I n symptomatic ...
Breaking Medicine Technology:Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 2Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 3Complete Data from RegeneRx Phase II Dry Eye Trial Published in Current Issue of Clinical Ophthalmology 4Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4
(Date:5/22/2015)... May 22, 2015 ZH ... IT solutions, announced today that Bill Lane, joins ... the developer of BlueEHS,a first of its kind, ... a customizable Electronic Health Records (EHR) with an ... a telemedicine-enabled comprehensive patient portal, and more. Combined ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... abstract entitled “Positivity Rates and Genotype Results in ‘Baby ... Action: Results from a Nationwide Lab Test Database” at Digestive ... conducted by Medivo’s Clinical Affairs and Analytics team members Carol ... Dhaliwal, MD; and Andrea Parker, MSI, along with Nancy Reau, ...
(Date:5/22/2015)... Jupiter, FL (PRWEB) May 22, 2015 ... Ed Begley, Jr., scheduled to broadcast on Friday, May ... PST, via Discovery Channel. , In this episode Innovations ... companies get back to business quickly through disaster recovery ... NDPTC, a company that works collaboratively to develop and ...
(Date:5/22/2015)... In April 2006, Veatch Consulting opened for ... they have concentrated their focus to working with over ... of this growth and their goals to better serve ... Colorado, Cleveland, Ohio, Houston, Texas and now Dallas, Texas. ... offices, dental start ups, orthodontic practices, pediatric dental practices, ...
(Date:5/22/2015)... May 22, 2015 Puritan Medical ... for the medical, diagnostic, environmental, and forensics industries ... of products in the US. At a time ... outside the US, Puritan remains committed to designing ... their Guilford, Maine facility. , Since 1919, Puritan ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Adds Bill Lane to Advisory Board 2Health News:Medivo Study Finds HCV Positivity Rates are 250% Higher Among Baby Boomers 2Health News:New Episode of Innovations Airing Friday, May 29, 2015 Via Discovery Channel 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2
... New Executive LeadershipKOBE, Japan, March 5 Sysmex ... medical diagnostics instrument manufacturer and laboratory information systems ... Corporate and its subsidiaries in the Americas, Europe ... Obe will return to Sysmex Corporate after a ...
... more than 3,000 women in the U.S. and southern ... a vaginal microbicide gel for preventing HIV infection in ... Retroviruses and Opportunistic Infections (CROI), one 0.5 % dose ... to cells in the genital tract, was 30% effective. ...
... printing superstore was honored for ecommerce expertise when President Michael Del ... version of the highly respected Entrepreneur magazine. , ... ... Del Chiaro for the interview based on his proven success in ...
... To Beaver, Star Jerry MathersJACKSON, Miss., March 5 ... will be stopping in Mississippi the week of March ... to help uninsured and financially-struggling Mississippians access information on ... free. With the unemployment rate in Mississippi (7.8 percent) ...
... Inc. (RPI), a wholly owned subsidiary of Ranbaxy ... received approval from the U.S. Food and Drug ... Hydrochlorothiazide (Quinapril + HCTZ) Tablets, 10mg/12.5mg, 20mg/12.5mg ... was submitted by Ranbaxy, from its Ohm Laboratories ...
... a penile extender every day for six months were able ... to 32% and their erectile function by up to 36%, ... issue of BJU International . , Researchers from San ... now suggesting that this treatment could provide a viable alternative ...
Cached Medicine News:Health News:Sysmex Corporation Announces Organizational Changes 2Health News:Clinical trial finds microbicide promising as HIV prevention method for women 2Health News:My1Stop.com President Michael Del Chiaro Interviewed by Entrepreneur.com for ecommerce Expertise 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 2Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 3Health News:Partnership for Prescription Assistance Prepared to Help Mississippi Workers Hurt by Recession 4Health News:Ranbaxy Secures Final FDA Approval for Quinapril Hydrochloride + Hydrochlorothiazide Tablets 2Health News:Penile extender increased flaccid length by almost a third says independent clinical study 2
... HIV-1 Antibody Test (Reveal Test) is MedMiras ... antibodies in human serum or plasma against ... in response to HIV infection. The Reveal ... membrane technology, and is comprised of a ...
... The OraQuick ADVANCE Rapid ... a single-use, qualitative immunoassay ... Human Immunodeficiency Virus Type ... 2 (HIV-2) in oral ...
... The advanced performance benefits ... been applied to the ... Implants) Upper Extremity Plates. ... combine to provide a ...
... of TiMAX material have been applied to a ... and an ultra-low profile combine to provide a ... extremity. , ,This complete set of periarticular plates ... , Fibula Composite Plate , Spider ...
Medicine Products: